TR200302242T2 - Pyrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrolopyrimidines as protein kinase inhibitors

Info

Publication number
TR200302242T2
TR200302242T2 TR2003/02242T TR200302242T TR200302242T2 TR 200302242 T2 TR200302242 T2 TR 200302242T2 TR 2003/02242 T TR2003/02242 T TR 2003/02242T TR 200302242 T TR200302242 T TR 200302242T TR 200302242 T2 TR200302242 T2 TR 200302242T2
Authority
TR
Turkey
Prior art keywords
pyrolopyrimidines
protein kinase
kinase inhibitors
prodrugs
oxides
Prior art date
Application number
TR2003/02242T
Other languages
Turkish (tr)
Inventor
Paul Cox Joseph
Tahir Majid Nadeem
Amendola Shelly
Stephanie Deprets Daniele
Edlin Chris
Brian Pedgrift Leslie
Halley Frank
Wards Michael
Baudion Bernard
Lain Mclay Mcfarlane
John Aldous David
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of TR200302242T2 publication Critical patent/TR200302242T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Bu bulus, formül (I)'e ait bilesiklerle, bu bilesiklerin N-oksitleri, ön ilaçlari, asit biyoizosterleri, farmasötik açidan kabul gören tuzlari veya solvatlariyla veya bu tuzlarin veya solvatlari N-oksitleri, ön ilaçlari veya asit biyoizosterleriyle, bu bilesikleri ihtiva eden kompozisyonlarla ve bu gibi bilesik ve kompozisyonlarin buna ihtiyaci olan bir hastaya uygulanmasini kapsayan tedavi metotlariyla ilgilidir.The present invention includes compounds of formula (I), N-oxides, prodrugs, acid bioisosters, pharmaceutically acceptable salts or solvates thereof, or N-oxides, prodrugs or acid bioisosters thereof. compositions and methods of treatment comprising administering such compounds and compositions to a patient in need thereof.

TR2003/02242T 2001-06-23 2002-06-21 Pyrolopyrimidines as protein kinase inhibitors TR200302242T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28

Publications (1)

Publication Number Publication Date
TR200302242T2 true TR200302242T2 (en) 2004-12-21

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/02242T TR200302242T2 (en) 2001-06-23 2002-06-21 Pyrolopyrimidines as protein kinase inhibitors

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
BRPI0416909A (en) * 2003-11-25 2007-01-16 Pfizer Prod Inc atherosclerosis treatment method
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
MY162590A (en) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
JP2010505962A (en) 2006-10-09 2010-02-25 武田薬品工業株式会社 Kinase inhibitor
EP3495369B1 (en) 2007-06-13 2021-10-27 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
NZ586642A (en) 2008-01-11 2012-04-27 Natco Pharma Ltd Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
PE20140407A1 (en) 2008-06-10 2014-04-25 Abbott Lab NEW TRICYCLIC COMPOUNDS
MX2011012262A (en) 2009-05-22 2012-01-25 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors.
EA025520B1 (en) 2009-05-22 2017-01-30 Инсайт Холдингс Корпорейшн N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
TW201802091A (en) * 2009-12-01 2018-01-16 艾伯維有限公司 Novel tricyclic compounds
SI3354652T1 (en) 2010-03-10 2020-08-31 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
BR112013012502A2 (en) 2010-11-19 2019-03-06 Incyte Corporation substituted cyclobutyl pyrrolopyridine and derivative pyrrolopyrimidine derivatives as jak inhibitors
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
JP6182593B2 (en) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド Substituted heterobicyclic compounds, compositions and medicaments and uses thereof
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
DK2877467T3 (en) 2012-07-26 2017-02-13 Glaxo Group Ltd 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
JP6318156B2 (en) * 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Compounds and methods for modulating kinases and indicators thereof
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
EA030705B1 (en) 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Processes and intermediates for making a jak inhibitor
AU2014244263A1 (en) 2013-03-13 2015-08-13 Abbvie Inc. CDK9 kinase inhibitors
BR112015021549A2 (en) 2013-03-13 2017-07-18 Abbvie Inc pyridine kinase cdk9 inhibitors
WO2014151444A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
AU2014231567A1 (en) 2013-03-14 2015-10-01 Abbvie Inc. Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
JP2016512560A (en) * 2013-03-14 2016-04-28 アッヴィ・インコーポレイテッド Pyrrolopyrimidine CDK9 kinase inhibitor
ES2792549T3 (en) 2013-08-07 2020-11-11 Incyte Corp Sustained-release dosage forms for a JAK1 inhibitor
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
SG10201913986YA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
PL3746429T3 (en) 2018-01-30 2022-06-20 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
EP3860998B1 (en) 2018-10-05 2023-12-27 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1441497A (en) * 1996-01-23 1997-08-20 Novartis Ag Pyrrolopyrimidines and processes for their preparation
BR9713552A (en) * 1996-11-27 2000-01-25 Pfizer Condensed bicyclic pyrimidine derivatives
ID26698A (en) * 1998-06-19 2001-02-01 Pfizer Prod Inc PIROLO COMPOUNDS [2,3-d] PYRIMIDINE
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
CZ2001959A3 (en) * 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidines functioning as kinase inhibitors
DK1235830T3 (en) * 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds as protein kinase inhibitors

Also Published As

Publication number Publication date
CN1518552A (en) 2004-08-04
ECSP034922A (en) 2004-04-28
JP2005508300A (en) 2005-03-31
WO2003000695A1 (en) 2003-01-03
RS99203A (en) 2006-12-15
EA007415B1 (en) 2006-10-27
NZ529766A (en) 2008-11-28
MEP19308A (en) 2010-06-10
JP4344607B2 (en) 2009-10-14
CN1294135C (en) 2007-01-10
SK15882003A3 (en) 2004-07-07
HUP0400300A3 (en) 2010-12-28
HUP0400300A2 (en) 2007-08-28
AU2002314325B8 (en) 2009-01-29
AU2002314325B2 (en) 2009-01-08
RS51698B (en) 2011-10-31
EE200400003A (en) 2004-02-16
EP1404676A1 (en) 2004-04-07
CA2451932A1 (en) 2003-01-03
CA2451932C (en) 2009-12-29
BR0210652A (en) 2004-08-10
EA200400073A1 (en) 2004-08-26
PL374096A1 (en) 2005-09-19
GB0115393D0 (en) 2001-08-15
UA76760C2 (en) 2006-09-15
TNSN03144A1 (en) 2005-12-23
EE05432B1 (en) 2011-06-15
CZ20033443A3 (en) 2004-03-17
WO2003000695A8 (en) 2004-03-11
OA12632A (en) 2006-06-14

Similar Documents

Publication Publication Date Title
TR200302242T2 (en) Pyrolopyrimidines as protein kinase inhibitors
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
TR200103186T2 (en) Quinoline derivatives as inhibitors of MEK enzymes
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
TR200401029T4 (en) Acylphenyl-urea derivatives, manufacturing methods and their use as pharmaceuticals
NO20025601L (en) Arylmethylamine derivatives for use as tryptase inhibitors
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
ATE296826T1 (en) PYRAZOLO(1,5)PYRIDINE DERIVATIVES
EP1248612A4 (en) Novel compounds and compositions as protease inhibitors
ATE371656T1 (en) HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
ATE307810T1 (en) IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS
TR200201205T2 (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
ATE300541T1 (en) PYRAZOLOPYRIDINE DERIVATIVES
DE60115466D1 (en) ACTIVE PROCESSORS OF IMIDAZOPYRIDINE DERIVATIVES
MXPA04001256A (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof.
EA200301203A1 (en) NEW COMPOUNDS AND COMPOSITIONS AS KATEPSIN INHIBITORS
DE60035429D1 (en) USE OF SULFODE HYDROABETIC ACIDS FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
MXPA04005809A (en) Protein kinase inhibitors.
TR200103457T2 (en) 4-Phenyl-Pyrimidine Derivatives.
MXPA04001328A (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof.
TR200402070T4 (en) Cyclobutene-dione derivatives and their use in the treatment of arteriosclerosis
NO20053876L (en) Carbonylamino-substituted acylphenylurea derivatives, process for their preparation and use thereof
ATE274515T1 (en) PYRAZOLOPYRIDINE DERIVATIVES
MXPA03008801A (en) Aryl oxime-piperazines useful as ccr5 antagonists.